What smart money is saying about Genmab
GMAB
No fund has written a full thesis on Genmab in our archive, but 1 fund letter reports a position in it, most recently Harding Loevner International Equity ADR in September 2026.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in Genmab on record in the archive was reported in Q3 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position
- September 2026
“Health Care added to relative returns. Genmab reported strong royalty growth from its two main drugs, Darzalex and Epkinly, and investors priced in optimism about upcoming clinical trial results.”
Genmab
Read the letters behind these Genmab positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger